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Viral respiratory infections (VRIs) are frequent after hematopoietic stem cell transplantation and constitute a
potential cause of mortality. We analyzed the incidence, risk factors, and prognosis of VRIs in a cohort of
transplanted patients. More frequent viruses were human coronavirus and human rhinovirus followed by ﬂu-
like viruses and adenovirus. Risk factors for death were lymphocytopenia and high steroid dosage.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Common viral respiratory infections (VRIs) are an impor-
tant cause of morbidity and mortality after allogeneic he-
matopoietic cell transplantation (HSCT) [1]. VRIs include
respiratory syncytial virus (RSV), inﬂuenza virus, para-
inﬂuenza virus (PIV), human adenovirus (AdV), human
rhinovirus (HRV), and, more recently, metapneumovirus
(MPV) and coronavirus (HCoV), which are prospectively and
routinely sought in our center. Incidences range from 1% to
30% depending on the type of virus, detection method, and
time from transplantation [1-3]. In the present single-center
study, we report on the incidence, clinical features, and
outcome of VRIs during a 4-year period in transplanted
patients.
METHODS
Patients who underwent a ﬁrst allogeneic HSCT in our center from
December 2006 to August 2010 and were regularly followed in our center
were eligible to be included in this study. Clinical and biological data were
extracted from our local database completed by chart review. During the
study period (December 2006 to June 2011), patients with respiratory
symptoms possibly related to a respiratory virus had nasopharyngeal aspi-
rates for PCR multiplex viral analysis [4] designed to detect RSV types A and
B; AdV; HRV; human MPV; HCoV 229E, OC43, and NL63; PIV-1 to -4;edgments on page 1241.
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14.04.004inﬂuenza virus types A and B; and 4 different bacteria (Chlamydophila
pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila, Bordetella
pertussis). Bacterial and fungal infections were documented by usual
methods including bronchoalveolar lavage in patients with a suspicion of
pneumonia.
Viruses were divided into 3 groups. HRV and HCoV share a more
benign symptomatology of the common cold and low direct mortality
rates and were thus compiled in one group [5]. Given their worse and on
occasion fatal outcomes in the post-transplant setting, RSV, MPV, PIV, and
inﬂuenza virus infections were gathered into a second ﬂu-like group
[1,6,7]. AdV was allocated to a separate third group because it can
disseminate [8].
Patients were analyzed based on their ﬁrst episode of VRI according to
the virus species or group. Death was considered as a competing event for
VRI. Cumulative incidence of VRI was estimated using usual methodology
for the ﬁrst VRI of any virus and then for the ﬁrst VRI by each of the 3 groups
of viruses. The association of baseline characteristics with the risk of VRI was
analyzed using Cox proportional cause-speciﬁc hazards model. For models
involving all VRIs by different virus groups for a patient (whether at the
same time or not), a robust sandwich estimator of the variance of the
parameters was used to account for potential correlation at the patient
level. Given patients’ follow-up, all time-to-event data were censored at
36 months after transplant. Analyses were performed using the R statistical
software version 2.15.2.RESULTS
With a median follow-up of 23 months, 166 VRIs were
diagnosed in 131 of 378 patients in a median of 4 months
after HSCT; among these patients, 119 were diagnosed in
outpatients. The 166 VRIs were distributed as follow: 16 AdV,
84 HCoV/HRV, and 66 ﬂu-like, including 14 inﬂuenza virus,
23 PIV, 17 RSV, and 12 human MPV. Characteristics of
patients and VRIs are shown in Table 1. Clinical presentations
of VRIs did not differ between the different virus types.
Copathogens were present in 45% of cases.
Table 1
Characteristics of the Cohort of Transplanted Patients and Patients with VRIs per Groups: (1) AdV, (2) HCoV/HRV, and Inﬂuenza, PIVs, HumanMPV, and RSV (Flu-
Like)
Characteristics Whole Cohort All VRI AdV HCoV/HRV Flu-Like
Number of patients 378 166 16 84 66
Age at transplant, yr (range) 43 (5-68) 39 (9-66) 28 (15-59) 41 (9-66) 40 (14-66)
Gender, n (%)
Female 140 (37) 63 (38) 5 (31) 37 (44) 21 (32)
Male 238 (63) 103 (62) 11 (69) 47 (56) 45 (68)
Hematological disease, n (%)
Malignancy 326 (86.2) 158 (95) 16 (100) 80 (95.2) 62 (94)
Nonmalignancy 52 (13.8) 8 (5) 0 4 (4.8) 4 (6)
Stem cell source, n (%)
Bone marrow 82 (21.7) 15 (9) 1 (6) 7 (8) 7 (11)
Peripheral stem cells 257 (68) 141 (85) 14 (88) 71 (85) 56 (85)
Cord blood 39 (10.3) 10 (6) 1 (6) 6 (7) 3 (5)
Donor type, n (%)
HLA-identical sibling 181 (47.9) 73 (44) 6 (38) 35 (52) 32 (49)
HLA-matched unrelated 128 (33.9) 64 (39) 7 (44) 34 (40) 23 (35)
HLA-mismatched unrelated 69 (18.3) 28 (17) 3 (19) 15 (18) 10 (15)
Myeloablative conditioning regimen 151 (39.9) 37 (22) 4 (25) 21 (25) 12 (18)
Median months from transplant to VRI (interquartile range) 4 (2-7) 4 (2-11) 3 (1-5) 4 (2-8)
At time of VRI
Active GVHD* 38 (23) 5 (31) 21 (25) 12 (18)
Steroid dose  1 mg/kg/day 37 (22) 5 (31) 18 (21) 14 (21)
Neutropenia <.5 g/L 23 (14) 6 (38) 9 (11) 8 (12)
Lymphopenia <.5 g/L 62 (38) 9 (56) 29 (35) 24 (37)
Pneumoniay 55 (33) 7 (44) 26 (31) 22 (33)
Nosocomial VRI 47 (28) 7 (44) 25 (30) 15 (23)
Copathogenz 74 (45) 12 (75) 32 (38) 30 (45)
VRI outcome
Hospitalization, n (%) 51 (31) 5 (31) 22 (27) 24 (36)
Hypoxemia, n (%) 17 (10) 4 (25) 5 (6) 8 (12)
Mechanical ventilation, n (%) 3 (2) 1 (6) 1 (1) 1 (2)
Death within 3 mo, n (%) 16 (10) 3 (19) 6 (7) 7 (11)
* Active GVHD was deﬁned as GVHD not in partial or complete remission.
y Pneumonia was deﬁned as new pulmonary inﬁltrates on imagery.
z Copathogen was deﬁned as a second infection including opportunistic (cytomegalovirus), bacterial, or fungal infection.
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40% (95% conﬁdence interval [CI], 34% to 45) (Figure 1). The
hazard of infection by AdVwasmarkedly lower than for the 2
other virus groups (both P < .0001), whereas infection by
HCoV or HRV was more frequent than infection by ﬂu-like
viruses (P ¼ .053).
The only risk factor identiﬁed in univariable analysis for a
ﬁrst VRI or HCoV/HRV infection was a history of acute graft-
versus-host disease (GVHD) (hazard ratio [HR], 1.54; 95% CI,
1.05 to 2.27; P ¼ .027) or chronic GVHD (HR, 1.79; 95% CI, 1.11
to 2.91; P ¼ .018). In contrast, high-risk disease (NE,
P ¼ .0002), cord blood as the stem cell source (HR, 5.50; 95%
CI, 1.37 to 22.1; P), and donorerecipient HLA mismatch (HR,
3.60; 95% CI, 1.30 to 10; P ¼ .014) were risk factors for AdV;
malignancies, cord blood as the stem cell source (HR, 2.53;
95% CI, 1.07 to 5.97; P ¼ .034), and GVHD (HR, 1.72; 95% CI,
1.01 to 2.93; P ¼ .045) were risk factors for ﬂu-like viruses.
Of 131 patients infected with VRIs, 16 died within
3 months. Among these deaths, 8 patients died of viral
pneumonia in concomitance with another cause of death:
bacterial and/or fungal pneumonia (RSV n ¼ 1, AdV n ¼ 1),
uncontrolled GVHD (AdV þ HRV n ¼ 1, RSV n ¼ 1, HCoV
n ¼ 1), graft rejection and bacterial/fungal pneumonia (RSV
n ¼ 1, AdV n ¼ 1), or post-transplant lymphoproliferative
disease (HCov n ¼ 1). Univariable analysis of risk factors for
death at 3 months, identiﬁed active GVHD (odds ratio [OR],
2.99; 95% CI, 1 to 8.88; P ¼ .049), ongoing steroid therapy at
a dose of 1 mg/kg body weight or higher (OR, 7.59; 95% CI,
2.61 to 22.1; P¼ .0002), a lymphocyte count lower than .5 g/L
(OR, 5.34; 95% CI, 1.54 to 18.5; P ¼ .008), pneumonia at thetime of diagnosis (OR, 8.65; 95% CI, 1.07 to 70; P ¼ .043), and
the presence of a copathogen (OR, 4.26; 95% CI, 1.28 to 14.2;
P ¼ .018). Interestingly, the virus group and the time from
HSCT had no impact on mortality. Multivariate analyses
showed that 2 factors remained associated with increased
overall mortality: steroid dose over 1 mg/kg body weight
(OR, 8.29; 95% CI, 2.56 to 26.8; P ¼ .0004) and a lymphocyte
count lower than .5 g/L (OR, 4.73; 95% CI, 1.25 to 17.9;
P ¼ .022) (Figure 1).
DISCUSSION
Overall incidence of VRIs in our study was consistent with
the incidences reported by other teams using PCR to detect
viral infection (ie, higher than that of immunoﬂuorescence
or viral culture) [9]. A higher incidence of HCoV/HRV as
compared with other VRIs conﬁrms the ﬁndings of Milano
et al. [5]. However, unlike the systematic sampling in the
Milano study, our samples were only collected in patients
with respiratory symptoms. Patients only presenting mild
symptoms probably did not seek medical attention as often
as those with more severe infection. This selection bias can
explain (1) that all patients with VRIs in our study seem to
have similar clinical presentation, including similar pneu-
monia prevalence, and (2) an underestimation of general VRI
incidence. Our study includes patients followed up to 3 years
after transplantation showing that VRIs continue to occur at
a high frequency in the late post-transplant phase. Overall,
the long-term data on VRIs after allogeneic HSCT is limited.
Martino et al. [2] reported a 2-year incidence of VRIs detec-
ted by immunoﬂuorescence or viral culture close to our
Figure 1. Cumulative incidence of VRI and mortality within 3 months after VRI. (A) Cumulative incidence of ﬁrst VRI from any virus, the shaded region represents
the pointwise 95% conﬁdence interval. (B) Cumulative incidence of ﬁrst VRI by each of 3 virus categories. (C) Mortality incidence according to virus group: AdV,
HCoR and HRV, and ﬂu-like. (D) Mortality incidence according to steroid dose. (E) Mortality incidence according to lymphocyte count. (F) Mortality incidence
according to copathogen presence. Infections with different viruses found at the same time or at different times in a same patient were all analyzed, although only
the ﬁrst virus of each group was considered. Because this yields to clustering, data were analyzed using generalized estimating equations with a robust variance
estimator.
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Virus repartition differed from ours with a lower frequency
of HRV, which can be attributed to the lower sensitivity of
their detection method [2].
Previous acute and chronic GVHD or recipientedonor
HLA mismatch can be considered as surrogate markers of
immunity and increased the probability of VRI diagnosis,
suggesting that some patients are more susceptible to VRIs.
Both have been previously described as predisposing factors
of viral infection [2,8,10].
Finally, the mortality rate attributable to VRIs was not as
high as expected and was not associated with a particular
virus. In this study, the cause of death could not clearly be
concluded to be from VRIs: the patients who died from viral
pneumonia all had other signiﬁcant and potentially fatal
comorbidities. We observed that risk factors for mortality in
VRI patients were steroid dose and lymphopenia, as reported
in other studies, although we cannot discriminate if these
risk factors are speciﬁc for patients with VRIs or common to
all transplanted patients [1,6,10,11]. Indeed, steroid and
lymphopenia reﬂect a poor general condition of the patient,
severe GVHD, and/or delayed immune reconstitution. Be-
cause VRI was not a risk factor for overall mortality in this
cohort, one can argue that the immune status might have
more of an impact than the infection itself (data not shown).
It is noteworthy that in this long-term study, the time from
transplantation to VRI had no effect on the prognosis, prob-
ably because the general status of the patients has a higher
impact on the outcome.
Finally, although the direct mortality rate appears to be
low, we have to keep in mind that fatal VRIs can occur in
severely immunocompromised patients. Furthermore, we
cannot exclude that later complications indirectly caused by
VRIs can increase late mortality such as noninfectious res-
piratory disease or secondary organ failure. To conclude, we
estimate that nasopharyngeal aspirates to identify VRIs in
patients with respiratory symptoms can be restricted to pa-
tients with a profound immune defect or those with lower
respiratory tract involvement who could beneﬁt from careful
clinical monitoring until recovery.ACKNOWLEDGMENTS
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